Pneumococcal conjugate vaccines have complex sugar molecules ... receive Capvaxive if they have previously been vaccinated with PCV13 and PPSV23. PCV13, also known as Prevnar 13, was approved ...

Widespread use of PCV13, which covers additional serotypes ... After the introduction of pneumococcal conjugate vaccine (PCV)-7, emergence of non-PCV7 serotypes, especially 19A, is prominent ...

The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.

The 15-valent conjugate vaccine was at least as effective ... to steal a march on Pfizer in the large paediatric pneumococcal vaccine category, as its rival is around a year away from reporting ...

PCV13 [pneumococcal 13-valent conjugate vaccine], or cohort 3: PPSV23 followed by or preceded by PCV13, PPSV23 preceded by PCV15 [pneumococcal 15-valent conjugate vaccine], or PCV15 alone).

Babies treated with antibiotics in the first few weeks of their life are likely to show weaker immune responses to essential ...

Merck MRK announced that the European Commission (“EC”) has approved its 21-valent pneumococcal conjugate vaccine (“PCV”), Capvaxive, for the prevention of invasive pneumococcal disease ...

Capvaxive is a pneumococcal vaccine specifically designed to help protect adults ... for more cases of IPD in adults compared to PCV20 (pneumococcal 20-valent conjugate vaccine), as shown in these ...

After the introduction of pneumococcal conjugate vaccine (PCV)-7 ... in antimicrobial resistance and MDR in S. pneumoniae. PCV13 may contribute in reducing the spread of drug-resistant 19A ...